Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 8/20 | 0.46 |
| ▸ | DPP8 | Q6V1X1 | 5/20 | 0.46 |
| ▸ | DPP7 | Q9UHL4 | 5/20 | 0.44 |
| ▸ | CNR2 | P34972 | 4/20 | 0.34 |
| ▸ | CFD | P00746 | 3/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.32 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.32 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30874836 | 0.77 | CNR2 (0.37) | DPP4DPP8DPP7CNR2CFD | |
| SCHEMBL30874910 | 0.76 | CNR2 (0.39) | DPP4DPP8DPP7CNR2CFD | |
| SCHEMBL30874917 | 0.75 | CNR2 (0.41) | DPP4DPP8DPP7CNR2CFD | |
| SCHEMBL30874921 | 0.74 | CNR2 (0.34) | DPP4DPP8DPP7CNR2CFD | |
| SCHEMBL30874875 | 0.73 | CNR2 (0.39) | DPP4DPP8DPP7CNR2CFD | |
| SCHEMBL1493709 | 0.72 | PIN1 (0.40) | DPP4DPP8DPP7CNR2PIK3CA | |
| SCHEMBL12757999 | 0.72 | PIN1 (0.40) | DPP4DPP8DPP7CNR2PIK3CA | |
| SCHEMBL24665621 | 0.70 | CFD (0.37) | DPP4DPP8DPP7CFD | |
| SCHEMBL3725157 | 0.68 | PIN1 (0.40) | DPP4DPP8DPP7CNR2CFD | |
| SCHEMBL5207017 | 0.68 | PIN1 (0.40) | DPP4DPP8DPP7CNR2CFD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12534453-B2 | Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof | MAZE THERAPEUTICS, INC. (US) | 2026-01-27 | — | — | US | disclosed |
| US-20240246939-A1 | INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF | HERCULES CAPITAL, INC., AS AGENT | 2024-07-25 | — | — | US | disclosed |
| US-11814367-B2 | Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof | MAZE THERAPEUTICS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230104740-A1 | INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF | HERCULES CAPITAL, INC., AS AGENT | 2023-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11814367-B2 | Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof | GYS2, GYS1, PYGL | DPP4 3092/4885DPP8 3479/4885DPP7 3814/4885 |
| US-20230104740-A1 | INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF | GYS2, GYS1, PYGL | DPP4 3092/4885DPP8 3479/4885DPP7 3814/4885 |
| US-12534453-B2 | Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof | GYS1, GYS2, GBA1 | DPP4 3310/4885DPP8 3178/4885DPP7 3064/4885 |
| US-20240246939-A1 | INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF | GYS2, GYS1, PYGL | DPP4 3092/4885DPP8 3479/4885DPP7 3814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.